Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | NPC1 | O15118 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | MAPT | P10636 | 4/20 | 0.64 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | MAOB | P27338 | 1/20 | 0.63 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | AR | P10275 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | RECQL | P46063 | 1/20 | 0.53 |
| ▸ | CA12 | O43570 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5722821 | 0.86 | ALDH1A1 (0.58) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL5585419 | 0.84 | RAB9A (0.70) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| Iodide SCHEMBL8300108 | 0.83 | ALDH1A1 (0.52) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL1428881 | 0.81 | ESR1 (0.56) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL5722931 | 0.80 | ADORA3 (0.72) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL11475453 | 0.78 | NPC1 (1.00) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| 8-Methoxyflavone SCHEMBL26180800 | 0.78 | ALDH1A1 (0.74) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL11732417 | 0.77 | MAOB (1.00) | RAB9AKDM4ENPC1MAPTMAOA | |
| SCHEMBL5722865 | 0.77 | ALDH1A1 (0.66) | RAB9AKDM4ENPC1SMN1; SMN2MAPT | |
| SCHEMBL5723099 | 0.77 | ALDH1A1 (0.50) | RAB9AKDM4ENPC1SMN1; SMN2MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200324287-A1 | OLIGONUCLEOTIDE ENCODED CHEMICAL LIBRARIES | Plexium, Inc. (US) | 2020-10-15 | — | — | US | disclosed |
| EP-0771794-B1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO KK (JP) | 2006-05-03 | — | — | EP | disclosed |
| US-6716987-B1 | PHOSPHODIESTERASE IV INHIBITORS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2004-04-06 | — | — | US | disclosed |
| US-6514996-B2 | Derivatives of benzofuran or benzodioxole | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2003-02-04 | — | — | US | disclosed |
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | KYOWA HAKKO KOGYO CO., LTD. (JP) | 2002-09-12 | — | — | US | disclosed |
| EP-0771794-A1 | OXYGEN-CONTAINING HETEROCYCLIC COMPOUNDS | KYOWA HAKKO KOGYO CO., LTD. (JP) | 1997-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020128290-A1 | DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE | CBR1, CBR3, CYC1 | RAB9A 2778/4885KDM4E 3975/4885NPC1 956/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.